Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PurMed Global CBD Organic Gummies are an edible consumer wellness product containing 1200 mg of hemp-derived cannabidiol (CBD). Developed by PurMed Global, these gummies are intended for general wellness and symptomatic relief of stress and anxiety. CBD, the active ingredient, is a non-psychoactive cannabinoid that interacts with the body's endocannabinoid system. It is thought to exert its effects by modulating cannabinoid receptors (CB1 and CB2) and interacting with other signaling pathways, such as the serotonin 5-HT1A receptor. The product is marketed as a dietary supplement and carries a disclaimer that it has not been evaluated by the FDA for the treatment or prevention of any disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PurMed Global CBD Organic Gummies.